NKGN: NKGen Biotech, Inc. Stock

by  •  • Comments Off on NKGN: NKGen Biotech, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 21.04
Enterprise Value ($M) 48.59
Book Value ($M) -69.72
Book Value / Share -1.55
Price / Book -0.30
NCAV ($M) -84.12
NCAV / Share -1.87
Price / NCAV -0.25

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -5.35
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.02
Current Ratio 0.02

Balance Sheet (mrq) ($M)
Current Assets 1.25
Assets 15.65
Liabilities 85.36
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
08-22 13G CFIC-2015 NV Family Investments, LLC
05-10 13G/A Meteora Capital, LLC 0.00 -100.00
02-07 13G/A Adage Capital Partners Gp, L.l.c. 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-09-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REP
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-29 5,205 41,069 12.67
2025-01-28 6,898 40,844 16.89
2025-01-27 16,488 80,699 20.43
2025-01-24 49,900 159,545 31.28

(click for more detail)

Similar Companies
NAMS – NewAmsterdam Pharma Company N.V. NEUP – Neuphoria Therapeutics Inc.
NGNE – Neurogene Inc. NRIX – Nurix Therapeutics, Inc.
NTLA – Intellia Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io